Abeona Therapeutics (NASDAQ:ABEO – Get Free Report) posted its earnings results on Thursday. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.19, Zacks reports.
Abeona Therapeutics Trading Down 1.2 %
ABEO opened at $5.14 on Friday. Abeona Therapeutics has a 1-year low of $3.05 and a 1-year high of $8.45. The firm has a 50-day moving average price of $5.45 and a two-hundred day moving average price of $5.83. The stock has a market capitalization of $223.44 million, a PE ratio of -1.91 and a beta of 1.79. The company has a current ratio of 6.12, a quick ratio of 6.12 and a debt-to-equity ratio of 0.31.
Analyst Ratings Changes
A number of research firms have commented on ABEO. HC Wainwright restated a “buy” rating and issued a $15.00 price target on shares of Abeona Therapeutics in a research report on Wednesday, February 19th. Oppenheimer initiated coverage on Abeona Therapeutics in a report on Wednesday, March 5th. They issued an “outperform” rating and a $16.00 target price on the stock. Finally, StockNews.com lowered Abeona Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, February 22nd. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $17.50.
About Abeona Therapeutics
Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.
Recommended Stories
- Five stocks we like better than Abeona Therapeutics
- How to Plot Fibonacci Price Inflection Levels
- Word-of-Mouth Winners: 2 Stocks Growing Without Big Ad Budgets
- What is the S&P/TSX Index?
- Cybersecurity Stocks Surge as $32B Deal Reshapes the Industry
- What is diluted earnings per share (Diluted EPS)?
- Could Palantir’s R1 Deal Be the Catalyst for a Stock Surge?
Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
